37 citations · 75 across the 30 of their papers we have counts for
4 papers · 1 filter
A multi-arm multi-stage platform design that allows pre-planned addition of arms while still controlling the family-wise error
Peter Greenstreet, Thomas Jaki, Alun Bedding +2
There is growing interest in platform trials that allow for adding of new treatment arms as the trial progresses as well as being able to stop treatments part way through the trial…
Point estimation for adaptive trial designs I: a methodological review
David S. Robertson, Babak Choodari-Oskooei, Munya Dimairo +3
Recent FDA guidance on adaptive clinical trial designs defines bias as "a systematic tendency for the estimate of treatment effect to deviate from its true value", and states that…
Dose Finding Studies for Therapies with Late-Onset Toxicities: A Comparison Study of Designs
Helen Barnett, Oliver Boix, Dimintris Kontos +1
An objective of phase I dose-finding trials is to find the maximum tolerated dose; the dose with a particular risk of toxicity. Frequently, this risk is assessed across the first c…
A Comparison of Model-Free Phase I Dose Escalation Designs for Dual-Agent Combination Therapies
Helen Yvette Barnett, Matthew George, Donia Skanji +3
It is increasingly common for therapies in oncology to be given in combination. In some cases, patients can benefit from the interaction between two drugs, although often at the ri…